| Name | Title | Contact Details |
|---|
PERL Research is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HelixVM is a cutting-edge digital health start-up revolutionizing the way healthcare is delivered. Our goal is to free both physicians and patients from the repetitive and time-consuming aspects of routine care, while simultaneously increasing patient access to care and physician income. We understand that the largest healthcare issue today is the challenge of increasing capacity without increasing providers. That`s why we`ve developed innovative solutions that utilize technology to streamline the treatment process and optimize resource allocation. By harnessing the power of asynchronous medicine and AI, we are able to provide patients with fast and efficient access to care, while also freeing up physician time to focus on more complex and critical cases. At HelixVM, we believe that by empowering patients and providers with the tools they need to deliver and receive high-quality care, we can help to transform the healthcare industry. Whether you`re a physician looking for a more efficient and rewarding way to practice medicine, or a patient seeking convenient and accessible care, we are here to help. Join us on our mission to revolutionize healthcare delivery and improve patient outcomes.
CareAllies works side-by-side with health care providers to help improve the quality, value and experience of care for their patients, to make health care better for everyone. Our aim: To support doctor-patient-community engagement that enhances the quality and affordability of care. It`s how physicians and health systems will deliver sustainable value-based care and continue to thrive in the future.
Bluegrass Community Health Center is a community clinic that provides complete medical care to people in Lexington and surrounding counties.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.